SCHEMBL11944993

SCHEMBL11944993

CCCCCCCCCCCCCCCCCCOc1c(N2CCN(S(=O)(=O)c3cccs3)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
GAA P10253 1/20 0.52
TSHR P16473 1/20 0.52
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 3/20 0.46
DCTPP1 Q9H773 1/20 0.46
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.44
USP2 O75604 1/20 0.44
MAPK1 P28482 1/20 0.43
PKM P14618 4/20 0.43
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
JAK2 O60674 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943865 1.00 MAPT (0.52) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11943873 1.00 MAPT (0.52) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11944990 1.00 MAPT (0.52) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11944991 1.00 MAPT (0.52) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11943875 1.00 MAPT (0.52) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11943872 0.99 MAPT (0.52) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11943889 0.96 MAPT (0.53) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11945008 0.94 MAPT (0.54) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11944988 0.93 MAPT (0.52) MAPTGAATSHRKDM4EALDH1A1
SCHEMBL11943888 0.90 MAPT (0.61) MAPTGAATSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885GAA 21/4885TSHR 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.